Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD9829 · 1 trial · 1 indication
DLTs are dose-limiting toxicities as defined in the study protocol.
Frequency, severity and relationship to study drug of AEs and SAEs
Incidence of AEs/SAEs and PK data
| Arm | Type | Description |
|---|---|---|
| Module 1: Dose Escalation | EXPERIMENTAL | Ascending dose level cohorts of AZD9829 in AML and MDS participants. |
| Module 1: Dose Optimization | EXPERIMENTAL | Characterizing the safety, tolerability, PK/PD, and preliminary antitumor activity of AZD9829 in CD123+ R/R AML participants, based on the data collected during dose escalation, dose optimization and backfill. |
| Name | Type | Description |
|---|---|---|
| AZD9829 | DRUG | AZD9829 will be administered by IV infusion |
Inclusion Criteria: * ≥18 years of age; * CD123+ hematologic malignancy based on flow cytometry or immunohistochemistry by local laboratory; * R/R AML (except APL); * R/R HR-MDS with ≥5% bone marrow blast at time of inclusion; * Had at least 1 prior line of therapy at currents histology, and h...
AZD9829 is an investigational small molecule being developed for the treatment of hematological malignancies, which are cancers of the blood and bone marrow. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
AZD9829 is designed to target CD123, a protein expressed on the surface of certain cells in hematological malignancies. By targeting CD123, the drug aims to interfere with the growth and survival of cancer cells in these blood cancers.
AZD9829 is being developed by AstraZeneca PLC, a multinational pharmaceutical company traded on the stock exchange under the ticker symbol AZN. AstraZeneca is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
AZD9829 is in Phase 1 clinical development. This early-stage trial is designed to assess the drug's safety, tolerability, and pharmacokinetics in patients with CD123-positive hematological malignancies. The drug is investigational and has not received regulatory approval.
AZD9829 is being studied in a Phase 1 clinical trial registered as NCT06179511, titled 'Study of AZD9829 in CD123+ Hematological Malignancies.' This completed trial enrolled 56 participants across multiple countries, including the United States, Australia, China, Germany, Italy, Japan, South Korea, Spain, Taiwan, and the United Kingdom.
AZD9829 is a unique investigational compound developed by AstraZeneca. It is not known to have any alternative names or to be the same as any other approved or investigational drug. Its distinct chemical structure and target differentiate it from other therapies in development.